Rapid Therapeutic Science Stock Buy Hold or Sell Recommendation
| RTSL Stock | USD 0 0.00 0.00% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Rapid Therapeutic Science is 'Strong Sell'. The recommendation algorithm takes into account all of Rapid Therapeutic's available fundamental, technical, and predictive indicators you will find on this site.
Check out Rapid Therapeutic Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Rapid and provide practical buy, sell, or hold advice based on investors' constraints. Rapid Therapeutic Science. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
Rapid |
Execute Rapid Therapeutic Buy or Sell Advice
The Rapid recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Rapid Therapeutic Science. Macroaxis does not own or have any residual interests in Rapid Therapeutic Science or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Rapid Therapeutic's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Good | Details | |
Volatility | Out of control | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
Rapid Therapeutic Trading Alerts and Improvement Suggestions
| Rapid Therapeutic is way too risky over 90 days horizon | |
| Rapid Therapeutic has some characteristics of a very speculative penny stock | |
| Rapid Therapeutic appears to be risky and price may revert if volatility continues | |
| Rapid Therapeutic Science currently holds 150 K in liabilities with Debt to Equity (D/E) ratio of 1.13, which is about average as compared to similar companies. Rapid Therapeutic Science has a current ratio of 0.07, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Rapid Therapeutic until it has trouble settling it off, either with new capital or with free cash flow. So, Rapid Therapeutic's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Rapid Therapeutic Science sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Rapid to invest in growth at high rates of return. When we think about Rapid Therapeutic's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 534. Net Loss for the year was (2.87 M) with profit before overhead, payroll, taxes, and interest of 334. | |
| Rapid Therapeutic Science currently holds about 112.16 K in cash with (2.21 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 66.0% of Rapid Therapeutic outstanding shares are owned by corporate insiders |
Rapid Therapeutic Returns Distribution Density
The distribution of Rapid Therapeutic's historical returns is an attempt to chart the uncertainty of Rapid Therapeutic's future price movements. The chart of the probability distribution of Rapid Therapeutic daily returns describes the distribution of returns around its average expected value. We use Rapid Therapeutic Science price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Rapid Therapeutic returns is essential to provide solid investment advice for Rapid Therapeutic.
| Mean Return | 2.27 | Value At Risk | 0.00 | Potential Upside | 0.00 | Standard Deviation | 18.46 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Rapid Therapeutic historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Rapid Therapeutic Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Rapid Therapeutic or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Rapid Therapeutic's price will be affected by overall pink sheet market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Rapid pink sheet's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 2.27 | |
β | Beta against Dow Jones | -0.05 | |
σ | Overall volatility | 18.25 | |
Ir | Information ratio | 0.12 |
Rapid Therapeutic Volatility Alert
Rapid Therapeutic Science is displaying above-average volatility over the selected time horizon. Rapid Therapeutic Science is a penny stock. Even though Rapid Therapeutic may be a good instrument to invest, many penny pink sheets are speculative instruments that are subject to artificial stock promotions. Please make sure you fully understand upside and downside scenarios of investing in Rapid Therapeutic Science or similar risky assets. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings,sudden promotions and many other similar artificial hype indicators. We also encourage traders to check work history of company executives before investing in high-volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Rapid instrument if you perfectly time your entry and exit. However, remember that penny pink sheets that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Rapid Therapeutic Fundamentals Vs Peers
Comparing Rapid Therapeutic's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Rapid Therapeutic's direct or indirect competition across all of the common fundamentals between Rapid Therapeutic and the related equities. This way, we can detect undervalued stocks with similar characteristics as Rapid Therapeutic or determine the pink sheets which would be an excellent addition to an existing portfolio. Peer analysis of Rapid Therapeutic's fundamental indicators could also be used in its relative valuation, which is a method of valuing Rapid Therapeutic by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Rapid Therapeutic to competition |
| Fundamentals | Rapid Therapeutic | Peer Average |
| Return On Asset | -0.55 | -0.14 |
| Current Valuation | 13.08 M | 16.62 B |
| Shares Outstanding | 7.75 M | 571.82 M |
| Shares Owned By Insiders | 66.33 % | 10.09 % |
| Price To Book | 136.70 X | 9.51 X |
| Price To Sales | 193,667 X | 11.42 X |
| Revenue | 534 | 9.43 B |
| Gross Profit | 334 | 27.38 B |
| EBITDA | (1.48 M) | 3.9 B |
| Net Income | (2.87 M) | 570.98 M |
| Cash And Equivalents | 112.16 K | 2.7 B |
| Cash Per Share | 0.01 X | 5.01 X |
| Total Debt | 150 K | 5.32 B |
| Debt To Equity | 1.13 % | 48.70 % |
| Current Ratio | 0.07 X | 2.16 X |
| Book Value Per Share | (0.40) X | 1.93 K |
| Cash Flow From Operations | (2.21 M) | 971.22 M |
| Earnings Per Share | (0.51) X | 3.12 X |
| Number Of Employees | 8 | 18.84 K |
| Beta | -10.77 | -0.15 |
| Market Capitalization | 4.22 M | 19.03 B |
| Total Asset | 2.2 M | 29.47 B |
| Z Score | 16.8 | 8.72 |
| Net Asset | 2.2 M |
Rapid Therapeutic Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Rapid . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Rapid Therapeutic Buy or Sell Advice
When is the right time to buy or sell Rapid Therapeutic Science? Buying financial instruments such as Rapid Pink Sheet isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Rapid Therapeutic in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Software Thematic Idea Now
Software
Companies that develop and distribute software and software systems to individuals or business. The Software theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Software Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Rapid Pink Sheet
Rapid Therapeutic financial ratios help investors to determine whether Rapid Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Rapid with respect to the benefits of owning Rapid Therapeutic security.